Treatment for uterine myoma with a gonadotropin-releasing hormone superagonist

Tikhomirov A.L.

doi:https://doi.org/10.17116/rosakush201717588-90

Tikhomirov A.L.

Treatment for uterine myoma with a gonadotropin-releasing hormone superagonist

Authors:

Tikhomirov A.L.

More about the authors

Journal: Russian Bulletin of Obstetrician-Gynecologist. 2017;17(5): 88‑90

DOI: 10.17116/rosakush201717588-90

Read: 5727 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Tikhomirov AL. Treatment for uterine myoma with a gonadotropin-releasing hormone superagonist. Russian Bulletin of Obstetrician-Gynecologist. 2017;17(5):88‑90. (In Russ.)
https://doi.org/10.17116/rosakush201717588-90

Подписка 2026 Российский вестник акушера-гинеколога (Russian Bulletin of Obstetrician-Gynecologist)

Использование инфографики авторами научных работ

Close metadata

Abstract:

Gonadotropin-releasing hormone (GnRH) agonists have a therapeutic effect at the central and local levels and impair the function of the intracellular system for realization of the biological effects of growth factors, sex hormones, and other substances, which promote uterine myoma progression. Modification of the bureselin molecule blocks enzyme inactivation at positions 6 and 10, making the drug the most sustainable GnRH agonist.

Keywords:

uterine myoma

hormones

growth factors

apoptosis

neoangiogenesis

molecular structure of GnRH agonists

buserelin depot

Authors:

Tikhomirov A.L.

Close metadata

References:

Vickery D.H., John Nestor, Hafez E.S. LHRH and its analogs: contraceptive and therapeutic applications. MTP Press Limited, Lancaster, England. 1984.
Matson RL, Lieberman BA. Clinical Ivf Forum: Current views in assisted reproduction. Manchester Univ Pr. 1990.
BenRafael Z, Laufer N, Mashiach S, Schenker JG. Advances in assisted reproductive technologies. Israel. 1989.
Goodman and Gilman’s Manual of Pharmacology and Therapeutics. 11 edition. 2008.
Bifulco G, Miele C, Pellicano M. Molecular mechanisms involved in GnRH analogue-related apoptosis for uterine leiomyomas. Mol Hum Reprod. 2004;10:1:43—48.
Chegini N, Luo X, Ding L, Ripley D. The expression of smads and transforming growth factor beta receptors in leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy. Mol Cell Endocrinol. 2003;209:1-2:9—6.
Chegini N, Ma C, Tang XM, Williams RS. Effects of GnRH analogues, ‘add-back’ steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-beta expression. Mol Hum Reprod. 2002;8:12:1071—1078.
Di Lieto A, De Falco M, Pollio F. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas. J Soc Gynecol Investig. 2005;12:2:123—128.
Ding L, Xu J, Luo X, Chegini N. Gonadotropin releasing hormone and transforming growth factor beta activate mitogen-activated protein kinase/extracellularly regulated kinase and differentially regulate fibronectin, type I collagen, and plasminogen activator inhibitor-1 expression in leiomyoma and myometrial smooth muscle cells. J Clin Endocrinol Metab. 2004;89:11:5549—5557.
Ellsworth BS, Burns AT, Escudero KW. The gonadotropin releasing hormone (GnRH) receptor activating sequence (GRAS) is a composite regulatory element that interacts with multiple classes of transcription factors including Smads, AP-1 and a forkhead DNA binding protein. Mol Cell Endocrinol. 2003;206: 1-2:93—111.
Chegini N, Kornberg L. Gonadotropin releasing hormone analogue therapy alters signal transduction pathways involving mitogen-activated protein and focal adhesion kinases in leiomyoma. J Soc Gynecol Investig. 2003;10:1:21—26.